Literature DB >> 26705439

Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy.

Boni E Elewski1, Antonella Tosti1.   

Abstract

A number of comorbidities and risk factors complicate the successful management of onychomycosis. Underlying conditions and patient characteristics, such as tinea pedis, age, and obesity, contribute to risk, whereas comorbidities, such as diabetes and psoriasis, can increase susceptibility to the disease. There are limited data on treatment effectiveness in these patients. Here, the authors review post hoc analyses of efinaconazole topical solution, 10%, in mild-to-moderate onychomycosis and present new data in terms of age and obesity. The only post hoc analysis to report significant differences so far is gender, where female patients do much better; however, the reasons are unclear. The authors report significant differences in terms of efficacy in obese patients who do not respond as well as those with normal body mass index (P=0.05) and in patients who have their co-existing tinea pedis treated compared to those in whom co-existing tinea pedis was not treated (P=0.025). Although there is a trend to reduced efficacy in older patients and those with co-existing diabetes, differences were not significant. More research is needed in onychomycosis patients with these important risk factors and comorbidities to fully evaluate the treatment challengse and possible solutions.

Entities:  

Year:  2015        PMID: 26705439      PMCID: PMC4689496     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  29 in total

1.  Epidemiology and prevalence of onychomycosis in HIV-positive individuals.

Authors:  A K Gupta; P Taborda; V Taborda; J Gilmour; A Rachlis; I Salit; M A Gupta; P MacDonald; E A Cooper; R C Summerbell
Journal:  Int J Dermatol       Date:  2000-10       Impact factor: 2.736

2.  Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey.

Authors:  A K Gupta; N Konnikov; P MacDonald; P Rich; N W Rodger; M W Edmonds; R McManus; R C Summerbell
Journal:  Br J Dermatol       Date:  1998-10       Impact factor: 9.302

3.  Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients.

Authors:  Jacek C Szepietowski; Adam Reich; Emilia Garlowska; Marzena Kulig; Eugeniusz Baran
Journal:  Arch Dermatol       Date:  2006-10

4.  Skin and nail mycoses in patients with diabetic foot.

Authors:  M Papini; M Cicoletti; V Fabrizi; P Landucci
Journal:  G Ital Dermatol Venereol       Date:  2013-12       Impact factor: 2.011

5.  Onychomycosis: a significant medical disorder.

Authors:  R K Scher
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

6.  Efinaconazole Topical Solution, 10%: Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis.

Authors:  Bryan C Markinson; Bryan D Caldwell
Journal:  J Am Podiatr Med Assoc       Date:  2015-04-13

7.  Patients at risk of onychomycosis--risk factor identification and active prevention.

Authors:  A Tosti; R Hay; R Arenas-Guzmán
Journal:  J Eur Acad Dermatol Venereol       Date:  2005-09       Impact factor: 6.166

8.  Distribution of toenail dystrophy predicts histologic diagnosis of onychomycosis.

Authors:  Hobart W Walling; Patrick J Sniezek
Journal:  J Am Acad Dermatol       Date:  2007-03-26       Impact factor: 11.527

9.  Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10.

Authors:  Ted Rosen
Journal:  Cutis       Date:  2015-09

10.  Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review.

Authors:  Lisa Matricciani; Kerwin Talbot; Sara Jones
Journal:  J Foot Ankle Res       Date:  2011-12-04       Impact factor: 2.303

View more
  13 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

2.  Evaluation of an Explanted Porcine Skin Model to Investigate Infection with the Dermatophyte Trichophyton rubrum.

Authors:  Fritz Ka-Ho Ho; M Begoña Delgado-Charro; Albert Bolhuis
Journal:  Mycopathologia       Date:  2020-02-27       Impact factor: 2.574

3.  Fractional carbon dioxide laser and topical tioconazole in the treatment of fingernail onychomycosis.

Authors:  Rania Ahmed El-Tatawy; Heba Ahmed Aliweh; Doaa Salah Hegab; Raghda Ahmed Zaki Talaat; Maii Atef Shams Eldeen
Journal:  Lasers Med Sci       Date:  2019-04-25       Impact factor: 3.161

4.  Comparative Study of Traditional Ablative CO2 Laser-Assisted Topical Antifungal with only Topical Antifungal for Treating Onychomycosis: A Multicenter Study.

Authors:  Bhavana Rajbanshi; Liangliang Shen; Miao Jiang; Qingyu Gao; Xin Huang; Jiaoyang Ma; Jihong Wang; Yang Hu; Hongli Lv; Xiao Wu; Jingjun Zhao
Journal:  Clin Drug Investig       Date:  2020-06       Impact factor: 2.859

Review 5.  Efinaconazole in Onychomycosis.

Authors:  Aditya K Gupta; Mesbah Talukder
Journal:  Am J Clin Dermatol       Date:  2021-12-13       Impact factor: 7.403

Review 6.  The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.

Authors:  Aditya K Gupta; Rachel R Mays
Journal:  Skin Appendage Disord       Date:  2018-02-13

Review 7.  Meta-analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis.

Authors:  Verónica Velasquez-Agudelo; Jaiberth Antonio Cardona-Arias
Journal:  BMC Infect Dis       Date:  2017-02-22       Impact factor: 3.090

8.  Daily Application of an Aqueous, Acidifying, Peelable Nail Polish versus Weekly Amorolfine for Topical Onychomycosis Treatment: A Prospective, Randomized, Blinded Trial.

Authors:  Frank Eertmans; Nejib Doss; Bart Rossel; Els Adriaens
Journal:  Dermatol Ther (Heidelb)       Date:  2018-07-26

9.  Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis.

Authors:  Keyvan Pakshir; Mandana Kamali; Hasti Nouraei; Kamiar Zomorodian; Marjan Motamedi; Mozhgan Mahmoodi
Journal:  Sci Rep       Date:  2021-10-20       Impact factor: 4.379

Review 10.  Challenges and Opportunities in the Management of Onychomycosis.

Authors:  Julia K Christenson; Gregory M Peterson; Mark Naunton; Mary Bushell; Sam Kosari; Kavya E Baby; Jackson Thomas
Journal:  J Fungi (Basel)       Date:  2018-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.